Progress in the treatment of hypertension over the past 50 years is reviewed. While achievements have been considerable, they have sometimes been exaggerated by uncritical analyses and meta-analyses of trials. Data
Introduction: a case history
A 62-year-old male senior executive was referred for medical examination. A heavy cigarette smoker, he was known to have been hypertensive for at least 4 years, but remained untreated. His principal complaints were of cough, together with worsening fatigue and exertional dyspnoea over recent weeks. On examination he was found to have a blood pressure of 186/108 mm Hg. Clinically there was gross left ventricular enlargement, confirmed both electrocardiographically and radiologically. Arteriosclerotic changes were seen on examination of the optic fundi, but there were no retinal haemorrhages or exudates. There was proteinuria. A diagnosis of hypertensive heart failure was made, and therapy was begun with cardiac glycosides. Neither a diuretic, nor any other antihypertensive treatment, was given. 1 During the following 3 months, severe hypertension was repeatedly confirmed, values ranging around 218-240/118-130 mm Hg. Four months after the initial consultation he developed retrosternal pain radiating to both shoulders. Myocardial infarction was suspected, although serial electrocardiography over several days disclosed no diagnostic changes. Severe hypertension persisted throughout the next 6 months, during which he experienced variable but progressively worsening lassitude and dyspnoea, punctuated intermittently by episodes of nausea and diarrhoea. The patient continued to serve at least nominally as the head of his organization, albeit with manifestly diminishing effectiveness, and with frequent periods off work for rest and recuperation. On the occasion of an official photograph in connection with his occupation he had difficulty in holding up his head unaided, and another doctor who saw him then was 'shocked to see a dying man'. 2 A further physician, who was to observe him in more detail at that time, recorded that he was 'very sick . . . with all the symptoms of hardening of the arteries of the brain in an advanced stage . . . I doubt, from what I have seen, whether he is fit for his job here'. 3 Four days later the patient was noted to have pulsus alternans. Blood pressure readings continued generally high, varying from 170/88-240/130 mm Hg. Then, just over 1 year from the first consultation, the patient developed sudden severe headache, rapidly lost consciousness, and was found to have a right hemiplegia; he died 2 h later. His widow refused permission for post-mortem examination to be performed. That account 1 is of the last year of the life of an important historical figure, Franklin D Roosevelt, US President. The year in question, from March 1944 to April 1945, was one of the most fateful in the history of the Western world, and the patient was then supposedly in charge of the affairs of the most powerful nation in the Western alliance. The occasion which engendered such concern from the two independent physicians 2, 3 was the Yalta conference, held in February 1945. Mistakes made by the sick Roosevelt at Yalta have been widely held by historians to have led to major political problems over the ensuing 50 years. 4 The President's own physician indeed later speculated on 'what turn the subsequent course of history might have taken if modern methods for the control of hypertension had been available'. 1 Such methods were of course not at hand in 1945, but have been introduced, with progressive refinement, over the ensuing five decades. It may therefore be of interest to review the achievements of antihypertensive therapy during that period.
Complications of hypertension
The complications of hypertension, which we seek to correct and/or prevent with therapy, are:
5 malignant phase hypertension, in which the blood pressure has risen so high, especially if the increase has taken place rapidly, that fibrinoid arterial necrosis is occurring; hypertensive encephalopathy, nearly always, when it occurs, superimposed on the malignant phase; overt hypertensive heart failure; stroke, which can be haemorrhagic or thrombotic; an accelerated decline of renal function with age; and hypertension-associated coronary artery disease and its sequelae. It will be noted that Roosevelt manifested several of these complications in the last year of his life.
In scrutinising the capacity of antihypertensive therapy to limit complications, we are necessarily concerned exclusively with drug treatment. 5, 6 Surgical manoeuvres, including dorsolumbar sympathectomy and adrenalectomy, are no longer employed in this context, whilst a range of non-pharmacological approaches, whatever their effect may be on blood pressure, remain unassessed concerning any capacity to limit complications.
Early uncontrolled observations
With the introduction of the first effective antihypertensive drugs, it soon became apparent that they could reverse the malignant phase, provided that renal failure was not too advanced, and also relieve overt hypertensive heart failure. 5, 6 The prognoses, untreated, of these complications of severe hypertension were so rapidly and consistently dire, that controlled trials of therapy were unnecessary for the demonstration of benefit, and would, indeed, have been unethical. These positive observations of therapeutic benefit have been repeatedly confirmed clinically.
Controlled trials
However, the capacity of antihypertensive drug treatment to prevent the supervention of complications not yet manifested required the prosecution of controlled clinical trials. Such studies have been conducted with remarkably varying competence from the time of the pioneering work of Hamilton and his colleagues in England in 1964. 7 Because the evolution of increasingly more effective and acceptable antihypertensive agents has paralleled developing expertise in clinical trial methodology, it is perhaps inevitable that the frailties of some initial essays in this field have been exposed. 6 Even so, it is disturbing to find several commentators overlooking often major defects of certain trials, and, consequently, presenting over-optimistic interpretations of the benefits of therapy. Figure 1 is taken from a review I published in 1986 8 of some of the early trials of antihypertensive drug treatment. The curve illustrates schematically the distribution of diastolic blood pressures to be found in adult Western or Westernized populations. Notably, in 1986 the focus both epidemiologically and therapeutically was on the diastolic pressure value as presaging cardiovascular morbidity. It is now recognised that systolic pressure also requires to be considered when evaluating the dangers of hypertension, and in analysing trial outcome. Indicated on Figure 1 is the progressive lowering in trials conducted over the 21 years from 1964 of the threshold of presenting diastolic pressure above which a protective effect could be discerned with treatment. The most recent trial to be completed then, the first MRC trial 9 was, and remains, numerically the largest of such studies; it had shown that with treatment, there was statistically a protective Adapted from Robertson. 8 The first Australian report 141 put that threshold at 100 mm Hg; the later account 33 lowered it to 95 mm Hg. The other trials indicated are from refs. 7, 9, 10, 11. Hamilton et al, 7 MRC Working Party, 9 and Veterans Admin Coop Study Group. 10, 11 effect with presenting diastolic pressures as low as 90 mm Hg and upwards.
The inclusion of trials in Figure 1 should not be taken as suggesting that such studies were above reproach. In that of Hamilton et al, 7 for example, while it was the first controlled trial to evince benefit, patients were allocated to therapy alternately as they presented at the clinic, rather than at random, and for that reason Hamilton's study has often been excluded from meta-analyses.
The US Veterans Administration trial
The US Veterans Administration Study, 10, 11 although for many years providing much of the case for prophylactic antihypertensive drug treatment, has been subjected to severe criticism, and some regard it as now of historic interest only. Concerns about the VA Study have included the splitting of the trial into two parts after its commencement; the loss of many patients to follow-up; that those included had already very prevalent cardiovascular complications, and hence were unrepresentative of the bulk of patients presenting for therapy; and that the results were seemingly inspected continually and the trial discontinued arbitrarily when an apparently significant result was obtained. 6, 12 One critic wrote in 1983: 'The US Veterans Study broke almost every rule of trial design and analysis, and if it were offered to a medical journal today it would probably not be accepted for publication'.
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HDFP
Most concern then and subsequently however, has centred on the large US Hypertension Detection and Follow-up Program (HDFP), 13 of which the defects were so serious that I excluded it from Figure 1 . Patients qualifying and entering HDFP were randomly assigned to receive either special intervention (Stepped Care; SC) or the ostensible control group (Referred Care; RC). SC participants were given a free preset programme of antihypertensive drug therapy in special centres. They were also advised to avoid a high salt intake. Additionally, SC patients who were overweight, hypercholesterolaemic, or heavy smokers were offered counselling designed to control those risk factors. Further, the SC patients received substantial financial and other material support. Patients allocated to the 'referred care' group (RC), by contrast, were simply directed to their regular physician, to obtain whatever treatment he or she might deem to be appropriate. Thus HDFP did not have a strict control group; whilst, moreover, cardiovascular risks additional to hypertension were addressed. Further confusion resulted from the adoption of different diagnostic criteria of coronary artery disease in various subsequent analyses. [14] [15] [16] [17] In the event, lower blood pressures were achieved on average during the study in the SC as compared with the RC patients, and accompanying that, cardiovascular morbidity was also lower in the SC subjects, including, in some categories of patient, and varying with the definition employed, less prevalent coronary artery disease. However, not surprisingly given the trial design, mortality from a range of noncardiovascular disorders (gastrointestinal, respiratory, cancerous, and diabetic) was also lower, by some 36%, in the SC group, 13 almost certainly reflecting the more ready access to diagnostic and therapeutic facilities afforded to those patients. Amongst many critics of HDFP, one may be quoted here: 'The HDFP study ought to be rejected because it was not a proper trial of the treatment of hypertension . . . it was large and involved a lot of work and expense, but its value is very limited . . . [it] seems to show that good care is better than bad care, but it tells us little about hypertension'.
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The Collins et al meta-analysis
Considering these major defects, it is surprising that HDFP was included in a much cited meta-analysis by Collins and colleagues 15 of hypertension treatment trials, and was there said to be 'unconfounded' even though, for the reasons given above, it failed to meet the authors' own explicit definition of an unconfounded study. Perhaps even more surprisingly, coronary morbidity in HDFP in that metaanalysis was computed on the basis of the patients' self-assessment, an approach which had previously been rejected by some of those same authors, 16, 17 as wholly subjective, and hence prone to bias.
The Collins et al meta-analysis 15 did find that antihypertensive treatment lowered coronary morbidity (not coronary mortality) significantly, by a mean of 14%. That finding was, however, wholly a consequence of the very questionable inclusion, and even then employing dubious diagnostic criteria, of HDFP. 18 The meta-analysis additionally showed a highly significant 42% reduction in stroke with treatment, a finding which was simultaneously gratifying and puzzling, since the authors calculated that antihypertensive therapy had thus rapidly achieved 'virtually all the epidemiologically expected stroke Journal of Human Hypertension reduction'. 15 In a later, more detailed account 19 it was concluded 'results confirm the previous observation that the reduction in stroke conferred by just a few years' treatment represents much or all of the full, long-term potential effect of the blood pressure reduction achieved'. There are few diseases in which therapy is completely effective, and prophylactic drug use in hypertension appears an especially improbable candidate as an exception.
The Gueyffier et al meta-analysis
For the various reasons given and despite its frequent citation, I shall eschew the Collins et al metaanalysis 15 in this review of treatment benefits, and shall rely more on that by Gueyffier et al. 20 The latter excluded HDFP for the reasons already stated; moreover, the various treatment trials were there grouped according to the severity of hypertension at entry, the ages of the patients evaluated, and the clinical circumstances, an approach more discriminating than that of Collins et al. 15 Gueyffier et al 20 considered altogether 17 trials. They examined three studies 10, 21, 22 in marked hypertension (entry diastolic pressure 100-130 mm Hg). Amongst these the principal therapeutic benefit with drug therapy was an 89% reduction in congestive cardiac failure, P Ͻ 0.001. Two trials were considered in patients hypertensive following stroke. These were distinctly disparate. A single-centre English study 23 entered patients within 2 weeks of a stroke; amongst these therapy limited stroke recurrence. A larger multicentre American trial 24 admitted patients up to a year after a stroke; in this the only therapeutic benefit was a reduction in congestive heart failure (n = 0 vs 6; P Ͻ 0.02).
The most impressive results were found by Gueyffier et al 20 in treating hypertensive subjects aged 60 years and more. Seven such trials [25] [26] [27] [28] [29] [30] [31] were considered, and entry was variously according to systolic and/or diastolic hypertension. Overall there was a therapeutic reduction by 46% in congestive heart failure, by 34% in stroke, and by 23% in cardiovascular mortality (all P Ͻ 0.001); by 21% in coronary events (P Ͻ 0.01); and by 10% in all-cause mortality (P Ͻ 0.05).
Trials in mild-to-moderate hypertension in young or middle-aged subjects yielded much less impressive results. Five such 9, [32] [33] [34] [35] were evaluated (as mentioned HDFP was omitted), the entry diastolic pressure ranging from 85-114 mm Hg. The only significant benefit was a 49% reduction in stroke (P Ͻ 0.001); there was no significant therapeutic reduction in coronary morbid events.
Gueyffier et al 20 noted that in several trials, active drug was started in a proportion of patients allocated to placebo, thus eroding statistical power. When such bias was corrected, the estimate of benefit in treating hypertension in elderly subjects was improved, the projected number of strokes prevented per 1000 patient-years of therapy increasing from five to nine, and of coronary events prevented from three to four. In mild-to-moderate hypertension in younger patients a similar correction improved
S54
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Recent trials
Trial outcomes published subsequent to the Gueyffier meta-analysis have reinforced those conclusions, and have not greatly altered them. A Chinese study 36 which recruited patients over 60 years of age, with either systolic or diastolic hypertension, found on treatment a significant decrease in strokes and all cardiovascular events; as expected, coronary artery morbidity was very low in these Chinese patients. A European trial 37 of isolated systolic hypertension in elderly subjects also demonstrated a therapeutic reduction in stroke and total cardiovascular morbidity, but not in cardiac failure or coronary morbidity.
Drug treatment and renal function
The effects of therapy in slowing the accelerated decline of renal function evident in hypertension have been difficult to evaluate. Uncontrolled studies already mentioned 5, 6 have demonstrated clear benefits in this regard in malignant phase hypertension, a situation in which, untreated, rapidly advancing renal impairment is prominent. However, prospective trials in milder hypertension have been too brief, and the indices of renal function employed probably too crude, for any such benefit to be shown. 6, 38 Nevertheless, several retrospective analyses have indicated that effective blood pressure control can retard a decline in renal function. 6, 39, 40 
Shortcomings of antihypertensive treatment: reasons
The trials of antihypertensive drug treatment summarised briefly herein have thus revealed differential benefits from such therapy. Those complications to have been most evidently prevented or corrected are those most obviously a consequence of the high blood pressure as such, namely the malignant phase, overt heart failure, and stroke. It has indeed been further held that such therapeutic advantage concerns haemorrhagic rather than thrombotic stroke. 41, 42 Significant reduction in coronary morbidity has been found only in hypertensive persons over the age of 60, even though coronary events outnumber strokes in younger patients. 20 There is hence undoubtedly therapeutic shortfall concerning those complications related less directly to arterial hypertension, most particularly via atheroma (atherosclerosis).
An additional, rather different, deficiency of antihypertensive treatment has emerged, notwithstanding the claim made in the Collins et al meta-analysis 15 that such treatment might eliminate all the epidemiological risk of hypertension-related stroke. Several reports [43] [44] [45] of data from hypertension clinics have shown that morbidity and mortality in treated hypertensive patients have remained higher than in control subjects drawn from the same population, and this holds even for those complications such as stroke, known to be particularly responsive to antihypertensive treatment. Importantly, such clinic data have not shown a comparable excess of deaths from cancer, and the deficit evidently represents an inadequacy of antihypertensive treatment. The reasons for, and hence the possible rectification of, these therapeutic shortcomings in hypertension are frequently linked or overlap, and thus can usefully be considered together. [1968] [1969] [1970] [1971] [1972] [1973] [1974] [1975] [1976] [1977] [1978] [1979] [1980] [1981] [1982] [1983] . Administrative and therapeutic efficiency improved visibly both during and after that time. On that basis alone, one would now expect much better results than were obtained several decades ago. Even so, when those patients with treated diastolic pressures below 90 mm Hg were evaluated separately, morbidity still remained in excess of normal; thus the relative therapeutic deficit was probably not attributable solely to any limitations in the delivery of therapy.
Organisational aspects
First, and most obviously, 5,46 limited organisational skills would have constrained achievements in medical outcome. For example, the much-quoted report from the Glasgow Blood Pressure Clinic 44 derive from data obtained over a period of 15 years (
Inadequate blood pressure reduction
At least a proportion of the failure of therapy to eliminate fully the complications of hypertension seems to be attributable to inadequate blood pressure reduction. Surveys have indicated that fewer than 30% of patients have on-treatment pressures below 140/90 mm Hg, 47, 48 whilst most benefit is obtained by lowering the systolic to about 140 mm Hg and the diastolic to about 90 mm Hg, with slight additional advantage at lower values. 9, 48, 49 Failure to achieve such effective blood pressure reduction has two principal causes: intrinsic inadequacy of some antihypertensive drugs given either alone or in combination; and the presence of sideeffects, which will lead often to sub-optimal dosage and poor patient compliance.
The J-curve question
A contrary suggestion 50, 51 is that in hypertensive patients with coronary artery stenosis, therapeutic lowering of the diastolic pressure to the range 70-85 mm Hg might increase the danger of provoking myocardial infarction (the 'J-curve' concept). The HOT trial 48 was designed to illuminate this issue. It comprised three groups of patients, in whom the target diastolic pressures were respectively р90, р85 and р80 mm Hg. The results concerning complications for the three groups showed rather small differences; only the trend for the rate of all myocardial infarction to be less the lower the target pressure was of borderline significance. The lowest incidence of major cardiovascular events occurred at a mean achieved diastolic pressure of 82.6 mm Hg. While there was a slight increase in morbidity at lower diastolic values, this was not significant. Surprisingly, the HOT trial publication provided scant information 52 on the initially central issue, the important group of 3080 hypertensive patients with a history of coronary artery disease, although amongst these an achieved diastolic pressure below 81 mm Hg did not apparently carry extra risk. 53 Thus although the J-curve controversy continues, 54 it is not evidently a major practical therapeutic issue.
5
Adverse effects: drugs used in trials
A further caveat is that many of the drugs employed hitherto in the treatment of hypertension possess, in addition to their ability to lower blood pressure, a variety of potentially adverse cardiovascular effects, which may well have limited their capacity to reduce complications. There are obvious difficulties in computing such a hypothecated amalgam of merits and demerits, and, not surprisingly, heated controversies have arisen. In considering these discordant issues, it is first requisite to appraise which classes of drug have been employed on those treatment trials to have shown benefit in hypertension. As I have already discussed herein, there is in turn much disagreement on which trials have been sufficiently well designed and executed to warrant inclusion for evaluation. Nevertheless, the oftrepeated saw that the only drug classes to have been used in trials showing benefit are diuretics and betablockers is clearly false. 6, 46, 54, 55 Of 23 trials I surveyed in 1997, 6 diuretics were employed in 22, albeit in various types and doses, and with widely differing attempts at concurrent potassium conservation. Centrally-acting drugs were the next most often used, featuring in 18 trials (methyldopa in 11, rauwolfia in 10, and clonidine in one). Beta-blockers were employed in fewer than half, nine of the 23 trials. Hydralazine appeared in six, guanethidine in five, and a calcium antagonist in four, while a ganglion blocker, bethanidine, an alpha-blocker, and an angiotensin-converting enzyme (ACE) inhibitor, figured in one trial each. Unspecified supplementary drugs were prescribed in at least six of the 23 trials. Since that review appeared, four more large studies have been published, in three 36, 37, 48 of which the basic therapy was a calcium antagonist, and in the fourth 56 an ACE inhibitor. Furthermore, and most germanely, combined therapy, that is, the requirement to administer two or more drug classes together in order to achieve adequate control of blood pressure, was necessary in from 60-100% of patients in various trials. 6, 57 We may now consider some of the potential demerits of certain types of antihypertensive drug.
Diuretics: problems
Diuretics cause hypokalaemia and depletion of body potassium content, and hence can predispose to cardiac arrhythmias. 58 While any consequent risks have been discounted by some commentators, 59 others have been less complacent.
58,60-62 To cite one
Journal of Human Hypertension example, in the very large first MRC trial, sudden death rates per 1000 patient years in men, in which sex the great preponderance of such catastrophes occurred, were 2.7 in those patients allocated to receive thiazide treatment, as against 1.1 on betablocker, and 1.9 on placebo. 63 The difference between thiazide and beta-blocker in this respect was highly significant (P = 0.01). Thiazide diuretics cause elevation of plasma cholesterol and triglycerides. 64 The increase is in all fractions and the ratios of these therefore remain unchanged. This plasma cholesterol elevation is most marked in the first year of thiazide treatment and abates somewhat thereafter. 65, 66 The prognostic significance remains uncertain, although undoubtedly troubling. A further aspect of thiazide treatment is that fasting blood sugar may be elevated and the glucose tolerance test become diabetic. 64 Hypokalaemia appears to be implicated in this diabetogenic effect, possibly via an action on pancreatic islets.
Beta-blockers: problems
Beta-blocking drugs do not change total plasma cholesterol, but they alter the ratio of high density lipoproteins to that of low density plus very low density lipoproteins (HDL: LDL + VLDL) in a potentially adverse way. 67 Those beta-blockers with high intrinsic sympathomimetic activity have least effect whilst the beta-1 selective drugs are intermediate. Beta-blockers have also been noted to lead to hyperglycaemia when given long term. 67 Moreover, nonselective beta-blockers prolong insulin-induced hypoglycaemia while selective agents probably do not. Both non-selective and selective beta-blockers inhibit the tachycardia and palpitations accompanying hypoglycaemia.
Centrally-acting drugs: problems
The older types of centrally-acting drugs, rauwolfia derivatives, methyldopa, and clonidine, employed in many of the early treatment trials of hypertension, can cause drowsiness and depression, and indeed reports of suicide in patients taking reserpine prevented that drug from becoming popular in Britain.
5,68
Calcium antagonists: problems Dihydropyridine calcium antagonists have been indicated severally as provoking adverse coronary events in susceptible patients, [69] [70] [71] [72] [73] [74] of causing serious bleeding, 75, 76 of inducing aplastic anaemia, 77 and of predisposing to cancer 78 and suicide. 79 These various reports have in turn been severely criticised and the issues remain highly controversial.
80-84
Atherosclerosis and its consequences
A most obvious therapeutic deficiency concerns nevertheless, as described earlier, the comparative failure to limit the atheromatous (atherosclerotic) complications of hypertension. In retrospect the shortfall is hardly surprising. Early antihypertensive drugs were introduced almost exclusively according to their capacity to lower high blood pressure, and thus would be expected to confer less benefit regarding those complications only indirectly resulting from arterial hypertension. 6 Moreover, initial epidemiological and therapeutic attention was directed to the diastolic pressure, 6, 85 which is particularly associated with arteriolar lesions and cardiac failure. Systolic hypertension, which is of more recent interest, is now seen to be more closely related to arterial atheroma (atherosclerosis). Four cardiovascular accompaniments of hypertension which are attracting especial current therapeutic attention are left ventricular hypertrophy, reduced physical compliance in large arteries, increased media: lumen cross-sectional ratio in resistance arteries, and both physical and biochemical dysfunction of endothelium. These several abnormalities and their consequences are frequently interlinked.
Left ventricular hypertrophy
With the development of left ventricular hypertrophy in hypertension, the left ventricle remains capable of emptying well, although it fills poorly. Enddiastolic pressure is increased, plasma concentrations of atrial natriuretic peptide are elevated, coronary arterial filling is impaired, subendocardial ischaemia occurs, ventricular ectopic activity is prominent, and prognosis is worsened. 5, 85 Consequently, recent interest has centred on the capability of different classes of antihypertensive drug to reverse such left ventricular hypertrophy, on the as yet unproven assumption that any such effect would be beneficial. Three large but retrospective reviews [86] [87] [88] of this topic have returned rather differing results, perhaps not surprisingly given the unavoidable deficiencies of analyses of data obtained originally for other purposes. Classes of drug which appear effective in correcting left ventricular hypertrophy include sympatholytic agents, for example methyldopa; angiotensin-converting enzyme (ACE) inhibitors; calcium antagonists; and beta-blockers. Less clearly of value in this regard are diuretics and alpha-blockers; whilst the so-called direct-acting vasodilators hydralazine and minoxidil are ineffective. Two reports 89, 90 indicated that the non-peptide angiotensin II antagonist, losartan, might worsen left ventricular hypertrophy, although a later account 91 was more reassuring. Undoubtedly, appropriately designed prospective trials employing well-validated methods will clarify several presently obscure matters.
Large arterial changes
In hypertension, important changes take place in the walls of large arteries. 85, [92] [93] [94] [95] Physical compliance is diminished, whilst the response to constrictor stimuli is enhanced. With these features, systolic pressure is disproportionately increased, an aspect closely associated with left ventricular hypertrophy, and blood flow turbulence, which predisposes to the formation of atheroma, 5, 42 is worsened. Large arterial compliance is improved by ACE inhibitors, and by the combined beta-blocker/nitric oxide releasing drug nebivolol. Large arterial compliance is largely unchanged by propranolol, whereas it is worsened by hydralazine.
92-96
Small arterial changes
In hypertension, the cross-sectional wall:lumen ratio of resistance arteries is increased, a result mainly of remodelling of medial smooth muscle. 97, 98 This change both reinforces the progression of hypertension and limits the antihypertensive effectiveness of agents whose main action is to relax small arteries. Antihypertensive treatment using a range of drugs has been shown to diminish the wall:lumen ratio of resistance vessels. 99 Further, in a direct prospective comparison, an ACE inhibitor was effective in this regard, whereas a beta-blocker was not. 100 ACE inhibitors seem indeed to be especially valuable in this context.
101-103
Blood flow turbulence
Blood flow via a non-branching length of a large artery is characterised by a rapidly moving central axial stream, with a more sluggish peripheral boundary layer, an arrangement which limits endothelial damage from kinetic energy. 5, 42 However, when a large artery branches, axial stream impingement on the vessel wall at the bifurcation causes high shear endothelial damage, while opposite to this low shear boundary layer separation occurs. Both are sites where atheromatous (atherosclerotic) plaques form. This takes place rapidly, but to a limited extent, with high shear; more slowly, but eventually usually more extensively, with low shear. Flow turbulence exacerbates these trends. Moreover, in the presence of an atheromatous arterial stenosis, turbulence is further worsened, with more rapid blood flow occurring through the narrowing, and zones of stasis and recirculation distal to it.
New drug developments
Two newly-developed types of antihypertensive drug may prove to be especially effective in limiting the sequelae of disturbances of blood flow and of dysfunction of the endothelium. Bosentan 104 is an antihypertensive antagonist of endothelin receptors; since increased circulating endothelin has been found to be associated with especially extensive arterial atherosclerosis, therein lies the possibility of restricting the formation of hypertension-associated atheromatous lesions. 5, 105, 106 Nebivolol is a highly selective beta-1 blocker which has the further capacity to stimulate the endothelial release of nitric oxide; 107 with this combination it is hoped that effective blood pressure lowering will be combined with limitation of both structural and biochemical impairment of the endothelium. Likewise the now well-established ACE inhibitors, but not nifedipine, can improve endothelium-dependent vasodilatation in hypertensive patients, although the mechanism of action is not determined. 108 These matters are the subject of ongoing clinical trials.
Other interest has been in antihypertensive drugs also possessed of antiplatelet actions. These include some dihydropyridine type calcium antagonists and the combined serotonergic and alpha-adrenergic blocking agent ketanserin. 85, 109 However, with the reports of various haemorrhagic complications possibly resulting from the antiplatelet properties of certain calcium antagonists, 75, 76 enthusiasm for this approach temporarily waned, then revived with reports of the beneficial effects found with added aspirin in the HOT trial. 53 A range of other approaches continues to be explored. 106 While ACE inhibitors and non-peptide antagonists of angiotensin II have proved effective in lowering high blood pressure, inhibitors of the enzyme renin itself, potentially of major value, have so far been constrained by low oral bioavailability and brief duration of action.
Neutral endopeptidase inhibitors block the breakdown of vasodilator natriuretic peptides and so lower blood pressure. However, as monotherapy their antihypertensive action is weak. Nevertheless, combined inhibition of natriuretic peptide breakdown and of ACE could be promising. At least one such drug, omapatrilat, is currently being evaluated.
More speculative is genetic therapy, including the possibility of transfection with vectors enhancing the endogenous production of various antihypertensive and antihypertrophic substances.
Again, we may return to some early evidence. As mentioned above, centrally-acting antihypertensive drugs featured in a majority of trials which showed clinical benefit with antihypertensive therapy. 6 However, side-effects limited the popularity of the older agents reserpine, methyldopa and clonidine. 5 The recent introduction of imidazaline I 1 -receptor agonists such as moxonidine, which are effective in lowering blood pressure yet without the side-effect burden of the earlier drugs, could open exciting therapeutic avenues. 
Non-pharmacological treatment
I now turn to the vexed question of non-pharmacological therapy of hypertension. Although several of such non-pharmacological approaches have been widely advocated both as a prelude and as an accompaniment to drug therapy, none has yet been assessed concerning any capacity to affect the complications of hypertension. 5, 6 This scientific deficit, which might have been expected to engender caution, has sometimes, surprisingly to the present writer, contrarily been accompanied by strident advocacy.
Dietary salt
Perhaps the most prominent amongst several contentious aspects is whether or not an unnecessarily high dietary intake of sodium chloride ('salt') can cause or worsen hypertension. There can currently be few aspects of medicine so beset by zealotry and accusations of bad faith. [110] [111] [112] Requiring emphaJournal of Human Hypertension sis 111 is that the human population is unlikely to be homogeneous in response to variations in salt intake, a consideration which argues against the indiscriminate injunction of unsupervised salt restriction. Nevertheless, it is the case that many young hypertensive persons (ie, below about the age of 40) have a significant deficit of body sodium content, whereas older and more severely hypertensive persons frequently have body sodium excess. 113 Thus dietary salt restriction is unlikely to be generally helpful as a preventive measure, or therapeutically much useful in young patients, though it might reinforce drug treatment in many older and/or more severely hypertensive subjects. Meta-analyses of controlled randomised treatment trials have broadly confirmed these precepts, 114, 115 although at best the antihypertensive effect of salt reduction is modest. 111, 112, 114, 115 Moreover, because salt restriction elevates plasma renin, and raises the plasma LDL:HDL ratio, 115 both of which changes could predispose to adverse cardiovascular events, several commentators have expressed caution on this issue unless and until morbidity data are available. 111, 112, 115 Potassium, magnesium, calcium Modest but seemingly real antihypertensive effects have been noted with dietary supplementation of either potassium [116] [117] [118] [119] or magnesium. 120, 121 Any antihypertensive effect of dietary calcium reinforcement has both its advocates [122] [123] [124] and detractors.
125,126
Alcohol
There is clear evidence of an association between alcohol consumption and raised blood pressure, and of an antihypertensive effect of alcohol restriction. 5, [127] [128] [129] Further, it has been suggested that alcohol intake might be an independent risk factor for stroke. 130 However, this issue is complicated by repeated observations that moderate alcohol intake limits cardiovascular complications.
5,131-134
Caffeine
Caffeine ingestion has an acute pressor effect, 135 although current evidence is contrary to habitual coffee consumption raising blood pressure long term, 136 or to the dietary elimination of coffee possessing a worthwhile antihypertensive effect.
5
Marine oils
There are suggestive, but in the view of the present writer, 5 as yet inconclusive, data that the consumption of diets rich in marine oils containing polyunsaturated fatty acids such as eicosapentanoic acid and docohexanoic acid can lower blood pressure.
Weight reduction
Reduction of excessive body weight has consistently been demonstrated to lower high blood pressure. 5 In comparative trials, the effect has exceeded that of salt restriction. 111 There is usually no additive blood pressure reduction if the two measures are combined.
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Exercise
Regular physical exercise, independently of any accompanying weight reduction, can be an effective, and thus far uncontroversial, means of blood pressure reduction. 5, 137, 138 Psychological treatment A range of psychological or behavioural approaches, which include yoga, transcendental meditation, biofeedback procedures, and relaxation training, have been reported, at least short-term, and with dedicated therapists and subjects, to lower blood pressure. 139 However, the longer-term effects remain uncertain, the methods are unsuitable for broadscale application, and these approaches have faded from general advocacy. 5, 46 In many aspects, the non-pharmacological approach to antihypertensive therapy remains very unsatisfactory. There is obvious appeal to devotees of public 'healthism' 140 and to government administrators or others responsible for providing medical funds. Nevertheless it is disturbing that too often dispassionate appraisal has been displaced by discordant evangelism, exemplified by some contributions to the uncommunicative 'debates' concerning dietary salt intake. 110 Too often genuine and crucial uncertainties have been clouded by vehement invective. Herein clinical science has been ill served.
Cigarette smoking
Less controversial is the influence of cigarette smoking. 5 While the acute effects of smoking on arterial pressure are complex, and habitual smokers have lower pressures than do non-smokers, smoking clearly increases the likelihood of a wide range of cardiovascular complications, including stroke and coronary and peripheral arterial disease, and thus greatly compounds the risks of hypertension. Both fibromuscular dysplastic and atheromatous renal artery stenosis are more prevalent in smokers. The incidence of malignant hypertension is higher in smokers, and its prognosis when treated is poorer in those who continue to smoke. 141 Furthermore, the capacity of antihypertensive drugs to lower arterial pressure, and to limit a range of cardiovascular complications, is impaired in persistent smokers. Cessation of cigarette smoking lessens the vascular risk. Hypertensive patients especially should therefore be firmly enjoined not to smoke.
Conclusions
This review has shown that although antihypertensive drug therapy has brought substantial achievements, these have been distinctly limited, and that further improvements must be sought. While the malignant phase and overt hypertensive heart failure can be readily controlled, and stroke substantially prevented, much less impact has been made on hypertension-associated coronary artery disease and its consequences. I have tried herein to indicate how these problems might be approached. Drug therapy, as heretofore, must necessarily be central to our efforts. First, we should identify, and then address, specific pathophysiological disturbances in hypertension. This elusive goal, if attained, would permit more effective, and much better tolerated, treatment. We require therapy attended by fewer side-effects, be they symptomatic, biochemical, or pathophysiological, a need almost certainly likely to be met if the initial requirement of defining underlying pathophysiology noted above were to be realized. Therapy should also resolve left ventricular hypertrophy, improve large arterial compliance, diminish small arterial wall:lumen cross-sectional ratio, and preserve endothelial structure and function. Antiplatelet properties could be advantageous. Once-daily drug administration is desirable, and cheapness comprises an obvious attraction.
Despite often fervent advocacy, non-pharmacological antihypertensive treatment exhibits at present widespread inadequacies. More understanding is needed of the mechanism of nearly all of these approaches. Too often, over-credulous invocation is substituted for the critical evaluation of any adverse and beneficial influences on morbidity and mortality. A detailed, discriminating scrutiny should be an indispensable prelude to the general recommendation of such therapy.
I opened this review with a medical account of the last year in the life of Franklin Roosevelt. Figure  2 is the photograph taken at Yalta in February 1945, on the occasion when it was noted that he had difficulty even in holding up his head unaided. 2 Depicted sitting between Churchill and Stalin is the haggard Roosevelt, still clutching his cigarette, even though he was posing for an official photograph. Within a few weeks Roosevelt was to die from the consequences of untreated, indeed at that time untreatable, hypertension. Antihypertensive drugs were not available in 1945. If such therapy had been possible, history, and the picture (Figure 3 ), might have been very different.
